Yanting Wu

Dr. Yanting Wu

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
YWYanting Wu
Yanting Wu
LZLi-Shan Zhong
Li-Shan Zhong
CHChen Huang
Chen Huang
YGYu-Ying Guo
Yu-Ying Guo
FJFu-Jun Jin
Fu-Jun Jin
YWYifei Wang
Yifei Wang
Macrophage infiltration is one of the main pathological features of ulcerative colitis (UC) and ferroptosis is a type of nonapoptotic cell death, connecting oxidative stress and inflammation. However, whether ferroptosis occurs in the colon macrophages of UC mice and whether targeting macrophage ferroptosis is an effective approach for UC treatment remain unclear. The present study revealed that macrophage lipid peroxidation was observed in the colon of UC mice. Subsequently, we screened several main components of essential oil from Artemisia argyi and found that β-caryophyllene (BCP) had a good inhibitory effect on macrophage lipid peroxidation. Additionally, ferroptotic macrophages were found to increase the mRNA expression of tumor necrosis factor alpha (Tnf-α) and prostaglandin-endoperoxide synthase 2 (Ptgs2), while BCP can reverse the effects of inflammation activated by ferroptosis. Further molecular mechanism studies revealed that BCP activated the type 2 cannabinoid receptor (CB2R) to inhibit macrophage ferroptosis and its induced inflammatory response both in vivo and in vitro. Taken together, BCP potentially ameliorated experimental colitis inflammation by inhibiting macrophage ferroptosis. These results revealed that macrophage ferroptosis is a potential therapeutic target for UC and identified a novel mechanism of BCP in ameliorating experimental colitis.

1 April 2021 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
RWRongze Wang
Rongze Wang
YZYexuan Zhu
Yexuan Zhu
JCJingyi Chen
Jingyi Chen
YWYiliang Wang
Yiliang Wang
XSXiaowei Song
Xiaowei Song
YWYifei Wang
Yifei Wang

15 April 2021 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
YWYanting Wu
Yanting Wu
XSXiaowei Song
Xiaowei Song
SQShurong Qin
Shurong Qin
PCPengxiao Chen
Pengxiao Chen
LHLianzhou Huang
Lianzhou Huang
YWYifei Wang
Yifei Wang
As a novel heat shock protein 90 inhibitor, AT‑533 exhibits various biological activities in vitro, including anti‑viral, anti‑tumor and anti‑inflammatory activities. Moreover, AT‑533 gel, a gel dosage form of AT‑533, has been suggested to have anti‑keratitis and herpes simplex virus type‑1 infection‑induced effects on the skin lesions of animals. However, the safety evaluation of AT‑533 and AT‑533 gel has, to the best of our knowledge, not been examined in in vivo toxicological tests. Therefore, these toxicological tests were carried out in the present study. A 30‑day subacute toxicity test for AT‑533 was conducted at doses of 1, 2 and 4 mg/kg in Sprague‑Dawley rats, while that for AT‑533 gel was conducted using a single dose of 5 g/kg. The toxicological tests showed that a high‑dose of AT‑533 caused lethality and side effects in Sprague‑Dawley rats. However, no mortality, loss of appetite and body weight, adverse reactions, or toxicologically relevant alterations in hematology, biochemistry and macroscopic findings (except for skin) occurred in rats exposed to low‑dose AT‑533 and single‑dose AT‑533 gel (5 g/kg) during a 30‑day subacute dermic toxicity study. The aforementioned results suggested that AT‑533 gel is non‑toxic for Sprague‑Dawley rats, as shown by a dermic subacute toxicity test and that except for slight skin irritation, AT‑533 gel had almost no side effects when administered percutaneously for 30 days.

17 October 2026 in Pharmacological Research
Verified
Journal Article
Open access
YWYanting Wu
Yanting Wu
SYShikai Ye
Shikai Ye
HCHuanling Chen
Huanling Chen
JLJiahui Li
Jiahui Li
XPXiang Pan
Xiang Pan
WPWeilin Pu
Weilin Pu

1 March 2023 in Archives of Medical Science
Verified
Journal Article
Open access
ZZZhihong Zhang
Zhihong Zhang
CRChen Rubin
Chen Rubin
LLLu Liping
Lu Liping
MAMao Anpeng
Mao Anpeng
GHGuo Hui
Guo Hui
SZShan Zhenxiu
Shan Zhenxiu
[This retracts the article DOI: 10.5114/aoms.2019.86798.].

18 June 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
YWYanting Wu
Yanting Wu
SYShikai Ye
Shikai Ye
HCHuanling Chen
Huanling Chen
JLJiahui Li
Jiahui Li
XPXiang Pan
Xiang Pan
WPWeilin Pu
Weilin Pu
Background: Systemic sclerosis (SSc) is a devastating autoimmune disease characterized by multi‑organ fibrosis with limited therapeutic options.Methods: Using targeted metabolomics, we first observed that α‑KG, a key TCA‑cycle intermediate, was paradoxically elevated in bleomycin‑induced fibrotic lungs and in TGF‑β‑stimulated fibroblasts, prompting us to test whether exogenous supplementation could augment this compensatory response. We administered oral α‑KG in bleomycin‑induced skin and lung fibrosis mouse models.Findings: Oral α‑KG significantly attenuated dermal and pulmonary collagen deposition, reduced inflammatory infiltration, and improved survival. Integrated single‑cell RNA sequencing and bulk transcriptomic deconvolution unexpectedly identified endothelial cells as the predominant cellular target. α‑KG restored endothelial proportions in vivo, rescued angiogenic function and barrier integrity (CD31, eNOS, tight junctions) in HUVECs, suppressed TGF‑β/Smad activation, reversed metabolic repression, including fatty acid oxidation and mitochondrial ultrastructure defects, and upregulated NRF1.Interpretation: Collectively, these findings reveal that α‑KG exerts broad anti‑fibrotic effects by protecting endothelial function and inhibiting pro‑fibrotic signaling, highlighting its potential as a translatable metabolic therapeutic strategy for SSc.